DUAL TARGETED THERAPY IN CROHN'S DISEASE – CURRENT OPTIONS, CLINICAL EFFICACY, AND SAFETY PROFILE
DOI:
https://doi.org/10.31435/ijitss.4(52).2026.6923Keywords:
Crohn's Disease, Dual Targeted Therapy, Biologic Therapy, JAK Inhibitors, Mucosal Healing, Safety Profiles, Quality of LifeAbstract
Background and Aim: Monotherapy with biologic agents in patients with severe Crohn's disease (CD) is frequently limited by secondary loss of response or failure of subsequent treatment lines. Dual targeted therapy (DTT), combining two agents with distinct mechanisms of action (biologics or Janus Kinase [JAK] inhibitors), represents an innovative strategy for medically refractory CD. This review aims to evaluate the clinical efficacy, mucosal healing, and safety profiles of various DTT regimens based on literature published between 2019 and 2026.
Methods: Data were synthesized from meta-analyses, cohort studies, and real-world evidence (RWE) registries.
Results: DTT achieves a pooled clinical response rate of approximately 68% and clinical remission in 51% of patients with refractory CD. Mucosal healing (endoscopic remission) is achieved in approximately 34% of patients, and histological remission in up to 29%. Combinations of anti-IL-12/23 agents (ustekinumab, risankizumab) with vedolizumab or anti-TNF-α agents, as well as combinations with JAK inhibitors (upadacitinib), show particularly high potential. Steroid-free remission and mucosal regeneration directly translate into reduced chronic fatigue, improved nutritional status, and enhanced quality of life (QoL). The overall rate of serious adverse events (SAEs) is approximately 8.3%, which is comparable to monotherapy in similarly advanced patient cohorts.
Conclusions: DTT represents a promising therapeutic strategy with an acceptable safety profile in medically refractory Crohn's disease. Clinical implementation requires standardized monitoring (TB/HBV/VZV screening, vaccination, therapeutic drug monitoring [TDM]) and further validation in randomized controlled trials.
References
Gordon, H., Minozzi, S., Kopylov, U., Verstockt, B., Chaparro, M., Buskens, C., et al. (2024). ECCO guidelines on therapeutics in crohn's disease: Medical treatment. Journal of Crohn's and Colitis, 18(10), 1531–1555. https://doi.org/10.1093/ecco-jcc/jjae091
Roda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., et al. (2020). Crohn's disease. Nature Reviews Disease Primers, 6(1), Article 22. https://doi.org/10.1038/s41572-020-0156-2
Casanova, M. J., Dragoni, G., Eder, P., Estevinho, M. M., Yanai, H., Ellul, P., et al. (2026). ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. Journal of Crohn's and Colitis, 20(7), Article jjag071. https://doi.org/10.1093/ecco-jcc/jjag071
Gergely, M., Papp, M., & Deepak, P. (2022). Management of refractory inflammatory bowel disease. Current Opinion in Gastroenterology, 38(4), 347–357. https://doi.org/10.1097/MOG.0000000000000841
Gisbert, J. P., & Chaparro, M. (2025). Combination therapy with biologics and/or small molecules in inflammatory bowel disease: A comprehensive review. Journal of Crohn's and Colitis, 19(9), Article jjaf161. https://doi.org/10.1093/ecco-jcc/jjaf161
Gisbert, J. P., Raine, T., Rubin, D. T., Beaugerie, L., Panaccione, R., Siegel, C. A., et al. (2026). ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. Journal of Crohn's and Colitis, 20(7), Article jjag066. https://doi.org/10.1093/ecco-jcc/jjag066
Marín-Jiménez, I., Sierra-Ausín, M., Letosa-Abián, T., Aparicio, J., Montoto-Otero, C., Pérez-Gisbert, J., et al. (2025). Synergistic effects of vedolizumab and JAK 1,2,3 inhibitors in crohn’s disease: Insights from a systems biology and artificial intelligence-based approach. Frontiers in Immunology, 16, Article 1699203. https://doi.org/10.3389/fimmu.2025.1699203
Colombel, J. F., Ungaro, R. C., Sands, B. E., Siegel, C. A., Wolf, D. C., Valentine, J. F., et al. (2024). Vedolizumab, adalimumab, and methotrexate combination therapy in crohn’s disease (EXPLORER). Clinical Gastroenterology and Hepatology, 22(7), 1487–1496.e12. https://doi.org/10.1016/j.cgh.2023.09.028
Altieri, G., Zilli, A., Parigi, T. L., Allocca, M., Furfaro, F., Fiorino, G., et al. (2025). Dual therapy in inflammatory bowel disease. Biomolecules, 15(2), Article 222. https://doi.org/10.3390/biom15020222
He, J., Tan, W., Sheng, Y., Chen, L., Feng, R., Wang, X., et al. (2025). Dual-targeted therapy for the management of refractory crohn’s disease: A retrospective cohort study. Clinical and Experimental Medicine, 25(1), Article 257. https://doi.org/10.1007/ 10.1007/s10238-025-01731-x
Xu, C., Huang, X., Zong, Y., Li, P., & Shi, H. (2026). Dual targeted therapy for refractory inflammatory bowel disease: A systematic review and meta-analysis. Journal of Evidence-Based Medicine, 19, Article jebm.70157. https://doi.org/10.1111/jebm.70157
Haase, A. M., Kelsen, J., Agnholt, J., & Bendix, M. (2026). Dual therapy for complex inflammatory bowel disease: Safety, clinical and steroid-free response. Clinical and Experimental Gastroenterology, 19, Article 632373. https://doi.org/10.2147/CEG.S632373
Hassan, S. A., Perry, C., Carey, P., Colohan, D., Eltaher, M. G., Dawoud, N., et al. (2025). Dual biologic therapy induces remission in refractory crohn’s disease with vedolizumab and ustekinumab. Crohn's & Colitis 360, 7(1), Article otae080. https://doi.org/10.1093/crocol/otae080
Fear, E. N., McDonald, B. D., Kennedy, M. S., Mathew, A. J., McMillan, R. H., Fine, Z. D., et al. (2026). Dual-targeted therapy with risankizumab and upadacitinib in medically complex crohn’s disease. Crohn's & Colitis 360, 8(2), Article otag049. https://doi.org/10.1093/crocol/otag049
Neurath, M. F., & Vieth, M. (2023). Different levels of healing in inflammatory bowel diseases: Mucosal, histological, transmural, barrier and complete healing. Gut, 72(11), 2164–2183. https://doi.org/10.1136/gutjnl-2023-329964
Srinivasan, A. R. (2024). Treat to target in crohn’s disease: A practical guide for clinicians. World Journal of Gastroenterology, 30(1), 50–69. https://doi.org/10.3748/wjg.v30.i1.50
Ahmed, W., Galati, J., Kumar, A., Christos, P. J., Longman, R., Lukin, D. J., et al. (2022). Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 20(3), e361–e379. https://doi.org/10.1016/j.cgh.2021.03.034
Danese, S., Sandborn, W. J., Colombel, J. F., Rutgeerts, P., Ghosh, S., Axler, J., et al. (2019). Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active crohn’s disease. Gastroenterology, 157(4), 1007–1018.e7. https://doi.org/10.1053/j.gastro.2019.06.038
Bargas, A., Torres, J., & Verstockt, B. (2025). Recent developments in biomarker guided therapy for crohn’s disease. Expert Review of Gastroenterology & Hepatology, 19(12), 1241–1255. https://doi.org/10.1080/17474124.2025.2590179
Fathallah, N., Pagano, M., Haouari, M. A., Barré, A., Atanasiu, C., Chambenois, E., et al. (2025). Effectiveness and safety of advanced dual-targeted therapy in refractory perianal crohn's disease. United European Gastroenterology Journal, 13, 1491–1501. https://doi.org/10.1002/ueg2.70059
Radford, S., Albuquerque, D. A. N., Najeeb, Z., Agarwal, D., John, A., Gordon, M., et al. (2026). Safety and efficacy of advanced combination therapies for treating inflammatory bowel disease in adults: A systematic review and meta-analysis. BMJ Open Gastroenterology, 13(1), Article e002307. https://doi.org/10.1136/bmjgast-2026-002307
Park, S. K., Ahuja, D., Yeh, K. H., Patel, S. B., Goodwin, S. W., Ma, C., et al. (2026). Comparative safety of advanced therapies for Crohn disease. JAMA Network Open, 9(2), Article e2557922. https://doi.org/10.1001/jamanetworkopen.2025.57922
Ingrasciotta, Y., Grova, M., Crispino, F., Isgrò, V., Calapai, F., Macaluso, F. S., et al. (2024). Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients. Minerva Gastroenterology, 70(1), 98–108. https://doi.org/10.23736/S2724-5985.21.02919-3
Clement, B., De Felice, K., & Afzali, A. (2023). Indications and safety of newer IBD treatments in the older patient. Current Gastroenterology Reports, 25, 160–168. https://doi.org/10.1007/s11894-023-00874-9
Meserve, J., Aniwan, S., Koliani-Pace, J. L., Shashi, P., Weiss, A., Faleck, D., et al. (2019). Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clinical Gastroenterology and Hepatology, 17(8), 1533–1540.e2. https://doi.org/10.1016/j.cgh.2018.09.035
Ahmed, E. F., Oribiana, C. C., Alahmad, M. A., Omar, N. M., Chitra Kumar, K. K., & Quraishi, M. N. (2026). Real-world effectiveness and safety of advanced combination treatment in patients with refractory inflammatory bowel disease. Advances in Therapy, 43(11), Article 3828. https://doi.org/10.1007/s12325-026-03828-5
Radford, S. J., Moran, G. W., & Czuber-Dochan, W. (2022). The impact of inflammatory bowel disease related fatigue on health-related quality of life: A qualitative semi-structured interview study. Journal of Research in Nursing, 27(8), 685–702. https://doi.org/10.1177/17449871211061048
Danese, S., Sands, B. E., Feagan, B. G., Jairath, V., Panaccione, R., Peyrin-Biroulet, L., et al. (2025). Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in crohn's disease. Contemporary Clinical Trials Communications, 48, Article 101574. https://doi.org/10.1016/j.conctc.2025.101574
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Michał Kiszka, Michał Uchański, Kinga Janiszek, Liwia Iwaniec, Wiktoria Jabłońska, Iga Januszaniec, Aleksander Mróz, Alicja Bonder, Julia Janicka, Jolanta Janasik

This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.

